EXRO TECHNOLOGIES INC.

Condensed Interim Financial Statements
For the six months ended June 30, 2017

(Unaudited)
(Expressed in Canadian dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, continuous disclosure requirement, if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim financial statements have not been reviewed by an auditor. The Company's independent auditor has not performed a review of these Unaudited Condensed Interim Financial Statements in accordance with standards established by the Chartered Professional Accountants for a review of unaudited condensed interim financial statements by an entity's auditor.

(Expressed in Canadian dollars)

As at		June 30, 2017		December 31, 2016
ASSETS				
CURRENT ASSETS				
Cash	$	2,403,975	$	80,280
Receivables (note 3)		53,513		31,082
Prepaid expense		9,591		-
TOTAL ASSETS	**$**	**2,467,079**	**$**	**111,362**
LIABILITIES				
CURRENT LIABILITIES				
Accounts payable and accrued liabilities (note 4)	$	1,081,814	$	739,334
Due to related parties (note 5)		837,668		823,316
Promissory notes payable (note 7)		529,000		235,000
TOTAL LIABILITIES		2,448,482		1,797,650
SHAREHOLDERS' EQUITY (DEFICIENCY)				
Share capital (note 8)		12,970,972		12,824,557
Subscription receipts (note 8)		2,148,390		-
Reserves		89,760		9,360
Deficit		(15,190,525)		(14,520,205)
TOTAL SHAREHOLDERS' EQUITY (DEFICIENCY)		18,597		(1,686,288)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)	**$**	**2,467,079**	**$**	**111,362**

Amalgamation agreement (note 11)

These condensed interim financial statements were authorized for issue by the Board of Directors on September 29, 2017. They are signed on the Company's behalf by:

"Mark Godsy" ______________________,

Director

"Jill Bodkin" ______________________,

Director

The accompanying notes are an integral part of these condensed interim financial statements

(Expressed in Canadian dollars)

		For the three months ended June 30, 2017		For the three months ended June 30, 2016		For the six months ended June 30, 2017		For the six months ended June 30, 2016
EXPENSES								
Filing fees	$	855	$	-	$	855	$	-
General and administrative		5,460		3,128		86,701		6,514
Marketing		-		-		34,006		-
Payroll and consulting fees (note 5)		259,476		37,335		413,221		92,980
Professional fees		71,757		4,719		120,843		7,930
Travel		10,855		-		15,622		1,555
TOTAL EXPENSES		(348,403)		(45,182)		(671,248)		(108,979)
OTHER INCOME (EXPENSES)								
Finance costs		-		(7,051)		-		(17,051)
Foreign exchange losses		505		-		(1,963)		-
Gain on forgives of loan payable		2,891		-		2,891		-
TOTAL OTHER INCOME (EXPENSES)		3,396		(7,051)		928		(17,051)
NET AND COMPREHENSIVE LOSS	$	(345,007)	$	(52,233)	$	(670,320)	$	(126,030)
Loss per share - basic and diluted	$	(0.01)	$	(0.00)	$	(0.02)	$	(0.00)
Weighted average number of common shares outstanding		32,878,321		31,120,193		32,391,338		31,120,193

The accompanying notes are an integral part of these condensed interim financial statements

Exro Technologies Inc.
Condensed Interim Statements of Shareholders' Equity
(Expressed in Canadian dollars)

	Number of outstanding shares		Share capital		Subscription receipts		Reserve		Deficit		Total shareholders' equity (deficit)
Balance, December 31, 2015	**31,120,193**	**$**	**12,764,645**	**$**	**-**	**$**	**9,360**	**$**	**(13,933,080)**	**$**	**(1,159,075)**
Net Loss	-		-		-		-		(126,030)		(126,030)
Balance, June 30, 2016	**31,120,193**	**$**	**12,764,645**	**$**	**-**	**$**	**9,360**	**$**	**(14,059,110)**	**$**	**(1,285,105)**
Private placement (note 8)	200,000		14,000		-		-		-		14,000
Shares issued for consulting fees	500,000		40,400		-		-		-		40,400
Shares issued for debt	78,750		5,512		-		-		-		5,512
Net Loss	-		-		-		-		(461,095)		(461,095)
Balance, December 31, 2016	**31,898,943**	**$**	**12,824,557**	**$**	**-**	**$**	**9,360**	**$**	**(14,520,205)**	**$**	**(1,686,288)**
Subscription receipts (note 8)	-		-		2,148,390		80,400		-		2,228,790
Shares issued for debt (note 8)	1,392,555		146,415		-		-		-		146,415
Net Loss	-		-		-		-		(670,320)		(670,320)
Balance, June 30, 2017	**33,291,498**	**$**	**12,970,972**	**$**	**2,148,390**	**$**	**89,760**	**$**	**(15,190,525)**	**$**	**18,597**

The accompanying notes are an integral part of these condensed interim financial statements

Exro Technologies Inc.
Condensed Interim Statements of Cash Flows
For the six months ended June 30, 2017 and 2016
(Expressed in Canadian dollars)

		2017		2016
OPERATING ACTIVITIES				
Net loss for the period	$	(670,320)	$	(126,030)
Items not involving cash:				
Accrued interest		-		17,051
Accrued management fees		-		50,000
Net changes in non-cash working capital items:				
Receivables		(22,431)		(2,251)
Prepaid expenses		(9,591)		-
Accounts payable and accrued liabilities		334,685		16,456
Cash used in operating activities		**(367,657)**		**(44,774)**
FINANCING ACTIVITIES				
Proceeds from promissory notes payable (note 8)		294,000		-
Proceeds from subscription receipts (note 9)		2,383,000		-
Subscriptions received		-		14,000
Advances from related parties		14,352		-
Cash provided by financing activities		**2,691,352**		**14,000**
Change in cash		2,323,695		(30,774)
Cash, beginning of the period		80,280		65,833
Cash, end of the period	**$**	**2,403,975**	**$**	**35,059**

The accompanying notes are an integral part of these condensed interim financial statements

1 NATURE OF OPERATIONS

Exro Technologies Inc. (the "Company") was incorporated under the laws of British Columbia on July 12, 2005.

The Corporation is working towards commercializing its patented Dynamic Power Management ("DPM") technology and proprietary system architecture for rotating electrical machines. The registered records office and place of business of the Company is Suite 2820 – 200 Granville Street, Vancouver, BC V6C 1S4.

On November 7, 2016, and as amended on November 15, 2016, the Company entered into an amalgamation agreement (the "Amalgamation Agreement") with BioDE Ventures Inc. ("BioDE") and BioDE's wholly owned subsidiary, 10889001 BC Ltd. ("Newco"). This amalgamation was completed on July 26, 2017 (Note 11).

2 BASIS OF PREPARATION

(a) Statement of compliance

These condensed interim financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 "Interim Financial Reporting". They do not include all of the information required for full annual financial statements and should be read in conjunction with the Company's audited annual financial statements for the fiscal year ended December 31, 2016, which have been prepared in accordance with International Financial Reporting Standards ("IFRS"). These financial statements follow the same accounting policies and methods of application as the Company's annual financial statements for the year ended December 31, 2016.

These condensed interim financial statements were authorized for issue on September 29, 2017 by the Board of Directors of the Company.

(b) Basis of preparation

These condensed interim financial statements have been prepared on a historical cost basis, except for certain financial instruments that have been measured at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

(c) Going concern of operation

These condensed interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business in the foreseeable future. The Company's ability to continue as a going concern and realize the carrying value of its assets is dependent on its ability to raise capital through equity and debt financing, the outcome of which cannot be predicted at this time. These matters indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. These condensed interim financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

(d) Functional and presentation currency

These condensed interim financial statements are presented in Canadian dollars, which is the Company's functional and reporting currency.

(e) Significant accounting judgements and estimates

The preparation of condensed interim financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed interim financial statements and the reported amount of expenses during the reporting period. Significant areas requiring the use of management estimates relate to the determination of deferred tax valuation allowance.

(Expressed in Canadian dollars)

2 BASIS OF PREPARATION (CONTINUED)

(e) Significant accounting judgements and estimates (continued)

Significant assumptions about the future and other sources of estimated uncertainty that management has made at the financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to the inputs used in the accounting for the deferred tax assets/liabilities.

3 RECEIVABLES

As at June 30, 2016, and December 31, 2016, receivables consist of GST.

4 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

		June 30, 2017		December 31, 2016
Accounts payable	$	800,659	$	703,334
Accrued liabilities		270,507		36,000
	$	1,071,166	$	739,334

5 RELATED PARTY TRANSACTIONS

Key management compensation

Key management consists of the Officers and Directors who are responsible for planning, directing and controlling the activities of the Company. As at June 30, 2017 and December 31, 2016, the following expenses were incurred to the Company's key management:

		December 31, 2016		December 31, 2016
Management fees	$	101,902	$	285,590
Share based compensation		-		-
	$	101,902	$	285,590

As at June 30, 2017, the Company was indebted to the CEO of the Company in the amount of $556,108 (December 31, 2016 – 495,924).

As at June 30, 2017, the Company was indebted to directors and officers of the Company in the amount of $237,973 (December 31, 2016 - $311,288).

All due to related party payable amounts are unsecured, non-interest bearing, and due on demand.

6 LOANS PAYABLE

During the six months ended June 30, 2017, the Company accrued interest expense of $nil (2016 – $10,000). This loan was repaid on August 25, 2016, with a payment of $137,390.

7 PROMISSORY NOTE PAYABLE

During the period, the Company borrowed additional promissory notes with BioDE of $294,000 for a total of $529,000. The loan is unsecured, non-interest bearing and is due on either the closing of a share exchange, merger, amalgamation arrangement or other similar transaction between the Company and the Lender or at the time such a transaction does not occur. On July 26, 2017, this transaction was completed and has been eliminated on consolidation.

8 SHARE CAPITAL

(a) Authorized common shares

There are an unlimited number of common shares without par value authorized for issue.

(b) Issued

At June 30, 2017, the Company had 33,291,498 common shares issued and outstanding (December 31, 2016 – 31,898,943).

During the six months ended June 30, 2017, the following share capital transactions occurred:

- On April 10, 2017, the Company completed a private placement of 11,915,000 subscription receipts at a price of $0.20 per subscription receipt for the proceeds of $2,383,000. Each subscription receipt entitles the holder to receive, without payment of any additional consideration or need for further action, one common share ("Share") of the Company. The Shares will be issued immediately before the amalgamation but after the share consolidation pursuant to the amalgamation (note 11). At conversion finder's fees $64,610 will have been paid in cash and finders fees of $89,600 will be issued as shares at a price of $0.20 per share.
- On April 27, 2017, the Company issued 1,392,555 common shares at a rate of $0.1051 per share to settle debts totaling $146,415.

During the year ended December 31, 2016, the following share capital transactions occurred:

- On August 23, 2016, the Company issued 200,000 shares for proceeds of $14,000;
- On September 30, 2016, the Company issued 500,000 shares to management and consultants for consulting fees with a fair value of $40,400.
- In December 2016, the Company issued 78,750 shares to a consultant to settle outstanding debt. The fair value of these shares was $5,512.

On October 23, 2016, the Company agreed to issue 12,610,166 common shares at a rate of $0.1051 per share to settle debts totalling $1,325,848. The issuance of these shares was conditional upon the Company completing its amalgamation agreement with BioDE. Pursuant to the amalgamation transaction, completed on July 26, 2017, these shares for debt were issued.

Stock options

The Company's incentive stock option plan (the "Option Plan") provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to directors, officers, employees and consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the Company may grant a total of 4,650,000 options. As at December 31, 2016, 2015 and 2015, there were no stock options granted or outstanding.

(Expressed in Canadian dollars)

8 SHARE CAPITAL

Warrants

	Number of Warrants	Price Per Share	Weighted Average Exercise Price
Balance, June 30, 2017 and December 31, 2016	362,178	$0.65	$0.65

		Number of Warrants	
Expiry Date	Exercise Price	June 30, 2017	December 31, 2016
August 29, 2019	$0.65	362,178	375,340
Total outstanding and exercisable		362,178	375,340

9 FINANCIAL INSTRUMENTS

The Company has designated its cash as fair value through profit or loss, accounts receivable as loans and receivables and accounts payable and accrued liabilities, related party payable and notes payable as other financial liabilities.

(a) Fair value

At June 30, 2017 and December 31, 2016, the carrying values of cash, accounts receivable, accounts payable and accrued liabilities, related party payable and loan payable approximate their fair values due to the relatively short period to maturity of those financial instruments.

The Company uses a fair value hierarchy to reflect the significance of the inputs used in making the measurements. The six levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3: Inputs that are not based on observable market data.

There were no transfers between Level 1, 2 and 3 during the period. At June 30, 2017 and December 31, 2016, the Company has designated its financial instruments as level 1.

(b) Financial risk management

The Company’s activities potentially expose it to a variety of financial risks, including credit risk, liquidity risk, and market risk.

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. As at June 30, 2017, the Company’s exposure to credit risk is the carrying value of cash. The Company reduces its credit risk by holding its cash at a major Canadian financial institution.

9 FINANCIAL INSTRUMENTS (CONTINUED)

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in raising funds to meet commitments associated with financial instruments. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through equity or debt financing.

June 30, 2017, the Company had cash of $2,403,975, accounts payable and accrued liabilities of $1,081,814 and related party payable of $837,668. All accounts payable and accrued liabilities are due within 90 days. The Company assesses the liquidity risk as low.

Market risk

Market risk consists of currency risk, interest rate risk and other price risk. These are discussed further below.

Foreign exchange risk

Foreign exchange risk is the risk that the fair value of future cash flows will fluctuate due to changes in foreign exchange rates. The Company has financial assets and financial liabilities denoted in US dollars and is therefore exposed to exchange rate fluctuations. The Company has not entered into any agreement or purchased any instruments to hedge the foreign exchange risk.

		June 30, 2017		**December 31, 2016**
Funds held in trust	$	12,897	$	31,629
Accounts payable and accrued liabilities		31,298		
	$	44,195	$	31,629

Based on the exposures as of June 30, 2017 and December 31, 2016, and assuming that all other variables remain constant, a 10% depreciation or appreciation of the US dollar against the Canadian dollar would result in an increase or decrease of approximately $3,000 (December 31, 2016 - $2,000).

Interest rate risk

Interest rate risk consists of two components:

i) To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk.
ii) To the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature and maturity.

Other price risk

Other price risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk or currency risk. The Company is not exposed to other price risk.

10 AMALGATION AGREEMENT

On November 7, 2016, the Company entered into an amalgamation agreement with BioDE Ventures Ltd. ("BioDE") and BioDE's wholly owned subsidiary, 1089001 BC Ltd. ("Newco"), to combine businesses with Newco. Upon amalgamation, the Company will exchange all shares issued and outstanding into BioDE shares at an exchange ratio of approximately one Exro share for 0.5257 BioDE shares. Upon the exchange, the Company's shareholders will hold approximately 86% of all BioDE shares issued and outstanding. On July 26, 2017, this amalgamation agreement was completed.

The Amalgamation will be accounted for as a reverse takeover whereby Exro will be reflected as the accounting acquirer and BioDE as the accounting acquiree. Management has evaluated that BioDE does not meet the definition of a business as defined by IFRS 3. Consequently, the Amalgamation will be accounted as an acquisition of BioDE's net assets and reporting issuer status by the issuance of shares of the Company to BioDE's shareholders. The BioDE share capital and retained earnings will be eliminated in the proforma consolidation. The cost of the transaction in excess of the net assets of BioDE will be reflected as an expense, being the cost of obtaining a listing of Exro's shares on the CSE.

11 SUBSEQUENT EVENT

On July 26, 2017, the 11,915,000 subscription receipts were converted into common shares at a price of $0.20 without payment of any additional consideration or need for further action.